FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer

Hematology / Oncology Approval

Source: FDA Center for Drug Evaluation and Research - What's New - June 29, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news